Campaign recommends against the use of benzodiazepine drugs for adults 65 years and older. The effect of direct patient education to catalyze collaborative care for reducing inappropriate prescriptions remains unknown.
Methods

Design, Setting, and Participants
A 2-arm, parallel-group, pragmatic cluster randomized clinical trial was conducted in Quebec, Canada. The trial protocol has been published. 24 The Research Ethics Board of the Centre de Recherche de l'Institut Universitaire de Gériatrie de Montreal approved the study protocol on July 26, 2009. All patients signed an informed consent form prior to the screening interview. Recruitment occurred between July 2010 and November 2012.
The study included 30 community pharmacies (cluster units) in the greater Montreal area. Eligibility criteria for clusters included local community pharmacies with 20% or more of their clientele consisting of older adults and a minimum of 50 eligible participants. A full list of pharmacies within 200 km of the research center was obtained through collaboration with the pharmacy chain's headquarters. This list was randomized, and pharmacies were systematically contacted by the research team to assess interest in participating.
The sampling frame for individual participants was a list of all adults 65 years and older receiving long-term benzodiazepine therapy from each participating pharmacy, provided to pharmacists by the central database system of the pharmacy chain. Eligibility criteria for individual participants included a minimum of 5 active prescriptions, one being an active benzodiazepine prescription (short, medium, or long acting) dispensed for at least 3 consecutive months prior to screening. Participants with polypharmacy (>5 medications) were recruited to extend the generalizability of the findings from this trial to the typical elderly benzodiazepine user with multimorbidity and associated polypharmacy. Exclusion criteria included a diagnosis of severe mental illness or dementia, an active prescription for any antipsychotic medication and/or a cholinesterase inhibitor or memantine in the preceding 3 months, and residence in a long-term care facility. All clients meeting study criteria received a recruitment mailing followed by telephone call invitations from their pharmacists. Patients who expressed interest in participating in the study were directed to the study team and screened for eligibility via in-home interviews with a research assistant. Clients who were unreachable after 3 attempts were not recontacted. During the in-home interview, patients with evidence of cognitive impairment, defined by a screening score less than 21 on the Montreal Cognitive Assessment, were excluded. 25 Baseline demographic data and information on the indication for and duration of benzodiazepine use, as well as any previous attempts at discontinuation, were collected. Health status was determined (excellent, very good, good, fair, or poor). The presence of an anxiety disorder was ascertained by a score of 9 or higher on the Geriatric Anxiety Inventory. 26
Intervention
The patient empowerment intervention consisted of an 8-page booklet based on social constructivist learning and selfefficacy theory, and its development and testing have been previously detailed. 24 The intervention comprises a self-assessment component about the risks of benzodiazepine use, presentation of the evidence for benzodiazepine-induced harms, knowledge statements designed to create cognitive dissonance about the safety of benzodiazepine use, education about drug interactions, peer champion stories intended to augment self-efficacy, suggestions for equally or more effective therapeutic substitutes for insomnia and/or anxiety, and stepwise tapering recommendations. 24 Tapering recommendations consist of a visual 21-week tapering protocol showing a picture-based diminishing schedule of full-pill, half-pill, and quarter-pill consumption. The visual schematic for the deprescribing protocol was proposed by consumers during the development and usability testing of the intervention to enable application to any benzodiazepine, regardless of dose. The intervention asks participants to discuss the deprescribing recommendations with their physician and/or pharmacist. The information is included in a letter-size paper handbook, with the language set at a sixth-grade reading level and written in 14-point font to facilitate accessibility to the material. The intervention was personalized according to the participant's pharmacy profile to include the name of the specific benzodiazepine the participants was taking. The intervention was mailed to the intervention group within 1 week of group allocation while the usual care (wait list) group received the educational tool 6 months following group allocation. A full version of the intervention is available in the eAppendix in the Supplement.
Outcomes
The primary outcome was complete cessation of benzodiazepine use in the 6 months following randomization. Cessation was defined as an absence of any benzodiazepine prescription renewal at the time of the 6-month follow-up that was sustained for 3 consecutive months or more, in the absence of substitution to another benzodiazepine. This was ascertained via pharmacy renewal profiles, which contained information on drugs purchased, dates of purchase, dose, and quantity served. Dose reduction was defined as a 25% or greater dose reduction compared with baseline sustained for 3 consecutive months or more. A baseline average daily dose per month was established using pharmaceutical profiles for the 6 months before randomization. Dose reduction was then calculated by comparing patients' average daily dose per month at 6 months after randomization compared with baseline. All doses were converted to lorazepam equivalents. To ensure an accurate representation of the pharmaceutical profiles, a list of pharmacies visited by participants was collected at baseline. At followup, patients were queried whether they switched pharmacies. A complete follow-up with the pharmacy in use at the 6-month follow-up was completed for all study participants. One investigator (P.M.) and 1 research nurse, blinded to group allocation, independently assessed outcomes according to a prespecified protocol. Agreement was obtained in 94% of cases, with differences adjudicated by a third investigator (C.T.).
Process Evaluation
After the primary end point had been ascertained using the pharmacy renewal profiles and in order to understand the events that occurred after receipt of the intervention, a 6-month semistructured interview was conducted by telephone with participants in the intervention group. Interviews lasted approximately 30 minutes. Participants were queried whether they had discussed the possibility of tapering their benzodiazepine medication with a physician, pharmacist, or both (yes/ no); what was decided during these discussions (open ended); whether tapering was attempted (yes/no); if any difficulties were encountered during the tapering process (open ended); reasons why any attempts failed (open ended); justification of why participants felt they did not want to discontinue their benzodiazepine medication (open ended); and satisfaction about learning about the risks of benzodiazepine use (yes/no).
Randomization and Allocation Concealment
A 1:1 allocation ratio was assigned by an independent statistician using nonstratified blocked randomization for groups of 4 pharmacies using computer-generated random digits. The study was described as a "medication safety study for older adults" without mention of benzodiazepines in particular; thus, participants remained blinded to the intervention at the time of enrollment. Group allocation was concealed from both the pharmacists and their clients by telling them that the intervention would be delivered to the clients at some point during the next year.
Sample Size
The study was powered at 80% (2-sided test α level of .05) to detect a minimal 20% difference in benzodiazepine therapy discontinuation due to the use of the intervention. 19,27-33 On the basis of the study results, we calculated a coefficient of variation (kappa) of 0.62, an intracluster correlation (ICC) of 0.008, and a median cluster size of 10.1, which resulted in a maximum design effect of 1.03. A minimal sample size per group of 60 individuals was therefore required. 34
Statistical Methods
Differences in baseline characteristics between groups were compared. To assess the primary outcome, we estimated the unadjusted risk difference (prevalence of the outcome) and 95% confidence intervals via generalized estimating equations (GEEs) using the participant as the unit of analysis, the pharmacy as the cluster, an exchangeable correlation coefficient to account for clustering effects of participants within each pharmacy, and discontinuation as a dichotomous outcome, assessed for each participant at 6 months after randomization. Both intent-to-treat (ITT) and per-protocol analyses were performed. Participants who were lost to follow-up were designated as having neither discontinued nor reduced the dose of benzodiazepines in ITT analyses. Generalized estimating equations with an identity link and an exchangeable correlation structure were used to account for possible correlation between individuals in the same cluster. 35 The number needed to treat was calculated as the inverse of the difference in absolute event rates between the experimental and control groups. 36 In secondary analyses, to control for possible confounding effects between groups, multiple logistic regression models were used, with age (<80 years vs ≥80 years), sex, education (high school or less vs college or university), health status (fair and poor vs other), benzodiazepine use for insomnia (yes/no), anxiety disorder detected with the Geriatric Anxiety Inventory (yes/no), benzodiazepine dose (<0.8-mg/d lorazepam equivalent vs ≥0.8 mg/d), 37 previous attempt at tapering (yes/no), duration of benzodiazepine use (<5 years or ≥5 years), and number of medications (<10 per day vs ≥10 per day) included in the model. To determine whether any of the aforementioned-listed characteristics differentially impacted on cessation rates, analyses were performed to estimate risk differences for each of the subgroups using interaction terms in the GEE model under ITT and per-protocol conditions. Proportions of participants reporting having discussed discontinuation with a physician or pharmacist were calculated.
Responses to the open-ended questions about failure to initiate discontinuation or abandonment of the tapering protocol were analyzed by content analysis according to emergent themes. All statistical analyses were run using RStudio 0.97.310.0, R-3.0.2, with statistics subpackage for GEE (RStudio Inc), an integrated development environment for R.
Results
Study Participants and Follow-up
A total of 165 community pharmacies were consecutively contacted over a 2-year period. Of these, 30 pharmacies (18%) consented. The most common reasons for nonparticipation in the project included lack of interest in participating in a research project (n = 63 [38%]), competing priorities (n = 30 [27%]), inability to reach the pharmacy owner to obtain consent (n = 24 [15%]), and inadequate personnel to aid recruitment (n = 16 [10%]) ( Figure 1) . The centralized electronic pharmacy records database identified 2716 potentially eligible clients in the participating pharmacies who were 65 years and older and who regularly renewed benzodiazepine prescriptions. Approximately 1 in 6 spoke with their pharmacist and agreed to meet with the research team. Four hundred clients were screened for eligibility, and 75% agreed to participate and were eligible to enroll in the trial. In total, 30 clusters and 303 eligible participants were randomized. Figure 1 depicts the study flow of the clusters and the participants for the trial. The median (range) number of participants per cluster was 10 (2-27).
Of the 303 participants randomized, 261 were available for 6-month follow-up (86%). There was no difference in the baseline characteristics of participants who withdrew or were lost to follow-up between or within trial arms. The mean (SD) age of the participants at baseline was 75 (6.3) years, 69% were women, and one-quarter (24%) had earned a college degree. The most common self-reported indications for taking a benzodiazepine were insomnia (60%) and/or anxiety (48%). Participants used benzodiazepines for mean duration of 10 years and had an average daily dose consumption of 1.3-mg equivalents of lorazepam ( Table 1) .
Outcomes
In ITT analyses, complete cessation was achieved in 40 of 148 participants (27%) compared with 7 of 155 controls (5%) (preva-lence difference, 23%; 95% CI, 14%-32%) ( Table 2) . There was a crude 8-fold higher likelihood of achieving discontinuation among those who received the intervention compared with controls (odds ratio, 8.1; 95% CI, 3.5-18.5) and an adjusted odds ratio of 8.3 (95% CI, 3.3-20.9) when all baseline characteristics were accounted for. Figure 2 illustrates the risk differences for discontinuation of benzodiazepines in subgroups of participants by treatment allocation using ITT analysis. No significant interactions were observed between the intervention assignment and participant characteristics, suggesting that the effect of the intervention was robust across variable predisposing characteristics. An additional 11% (95% CI, 6%-16%) of individuals who received the intervention achieved dose reductions. The number needed to treat for any discontinuation or dose reduction was 3.7 in ITT analyses (Table 2) . Perprotocol analysis yielded similar results.
Patient Empowerment and Process Evaluation
Six-month telephone follow-up interviews with all participants in the intervention group who completed the trial (n = 123) revealed that 62% initiated discussions about benzodiazepine therapy discontinuation with their physician and/or pharmacist, and 58% attempted discontinuation ( Table 3) . The majority (72%) of participants desiring discontinuation opted to follow the tapering protocol provided. Others required a customized tapering protocol because more than 1 benzodiazepine was being used or because the type of benzodiazepine pills or capsules could not easily be halved or quartered and substitution was required to appropriately taper. Of the 71 participants who attempted cessation, 38 (54%) were successful; 16 (22%) achieved dose reduction, of which one-third was continuing the tapering process; and 17 (24%) failed. Withdrawal symptoms such as rebound insomnia or anxiety occurred in 42% of participants attempting to taper. No major adverse effects requiring hospitalization were reported. Of the 40 participants, 5 (13%) who discontinued benzodiazepine therapy received substitutions with trazodone (3 cases), paroxetine (1 case), or amitriptyline (1 case). In 7 individuals who attempted to taper, complete discontinuation was discouraged by their health professional. Among the 52 recipients who elected not to taper, discouragement by their physician or pharmacist was the most common reason provided (n = 17 [33%]), followed by fear of withdrawal symptoms (n = 13 [25%]), lack of concern about taking benzodiazepines (n = 12 [23%]), and difficult life circumstances (n = 6 [12%]). Several participants reported that their physician discouraged use of the tapering protocol because of a perceived absence of adverse effects from their benzodiazepine use. Of the 123 participants, 120 (98%) acknowledged satisfaction with receiving medication risk information.
Discussion
Delivery of an empowerment intervention to engage older adults in discussing the harms of benzodiazepine use with their physician and/or pharmacist yielded a benzodiazepine discontinuation rate of 27% compared with 5% in the control group 
Strengths and Weaknesses of the Study
Strengths of this study include systematic recruitment of participants via community pharmacies; blinding of the study hypothesis from participants, physicians, pharmacists, and evaluators; and objective assessment of drug discontinuation rates from pharmacy prescription renewal profiles. Compared with previous studies, this trial exclusively targeted seniors older than 65 years, examined patient empowerment as a means of initiating shared decision making around potentially harmful medication, and addressed the issue from the patient's rather than the physician's perspective. 19, [27] [28] [29] 38, 39 One limitation is the 6-month time frame for outcome reporting. Longer follow-up times could reveal relapse rates or higher discontinuation rates as several participants who achieved dose reductions were still following the tapering protocol at study end point. Recruitment rates for pharmacies (18%) and individual participants (11%) were low and excluded potential participants with cognitive impairment. Despite this, selection bias is unlikely because neither pharmacists nor participants were aware of the primary outcome of the study other than it being a medication safety study for older adults. Pharmacies were recruited systematically across socioeconomic and geographic living areas around Montreal, and although data on participant income could not be collected, no differences between groups were observed on other variables that correlate with poverty in the senior population such as female sex, edu-cational status, and polypharmacy. 40,41 Subgroup analyses may have been underpowered to detect differences. Cursory content analysis of the events that followed receipt of the intervention may have been limited by patient recall and the nonintimate nature of the 6-month follow-up. The process of shared decision making around benzodiazepine therapy discontinuation and physicians' motivations for counseling against benzodiazepine therapy discontinuation could not be evaluated because there was no direct contact with physicians during the trial.
Relevance of the Findings and Implications for Clinicians
Our findings suggest that direct-to-consumer education successfully leads to discussions with physicians and/or pharmacists to stop unnecessary or harmful medication. Discontinuation or dose reduction of benzodiazepines occurred in more than one-third of the participants who received the empowerment intervention. The Beers criteria for inappropriate use of medications provide guidance for 53 drugs to be avoided in the elderly. 10 This trial only addressed deprescription of benzodiazepine medication, which arguably may be one of the most difficult classes of medication to withdraw because of psychological and physical dependence. 15, 42 Previous studies have examined the effect of other types of brief interventions by physicians on patient discontinuation of benzodiazepine use, as well as pharmacist-initiated communication with general practitioners to deprescribe potentially inappropriate medication. 31, 43, 44 Sending a letter of advice from family physicians to patients achieved a discontinuation rate of 24% at 6 months, but the effect size was reported as much lower because 12% of participants in the con- trol group also achieved discontinuation. 28 Our use of a cluster randomized design with prerandomization enrolment of participants may help explain the larger effect seen in the present study. Furthermore, the added value of directly educating the patient, in the absence of initial physician involvement, likely promotes patient buy-in for discontinuation at an early stage and allows the patient to act as a catalyst for initiating discussions about medication management, which is a more effective approach than the traditional paternalistic approach to patient care. 23 The booklet used for this trial, which directly delivers information on drug harms to patients, could be distributed in the nonresearch environment in pharma- cies or on the Internet in conjunction with other community education initiatives such as the American Geriatrics Society website (http://www.healthinaging.org), thus achieving widespread reach. Three issues arise for future consideration. First, participants reported that their physician discouraged discontinuation of benzodiazepines in several cases. Many physicians continued to perceive the benefits of benzodiazepines as outweighing their risks. 19 Second, benzodiazepines were sometimes substituted with equally harmful sedative medication. A similar phenomenon was found to occur in US nursing home residents when coverage for benzodiazepine medications was interrupted during implementation of the Medicare Part D reimbursement policy in 2006. 45 Continuing medical education to physicians about the harms of all sedative hypnotic medication may eventually overcome this obstacle. Third, pharmacists were solicited less often than physicians to discuss benzodiazepine therapy discontinuation. With the expanding scope of pharmacists' practice and an increasing em-phasis on interprofessional models of care, community pharmacists may be underutilized players to participate in efforts to reduce costly and unnecessary medical treatments. 46
Conclusions
Supplying older adults with evidence-based information that allows them to question medication overtreatment appears safe and effective and is consistent with the priorities expressed by the ABIM Choosing Wisely campaign. Without a direct-topatient educational component, promotional efforts for deprescription to physicians may fail or have a smaller impact. In an era of multimorbidity, polypharmacy, and costly therapeutic competition, direct-to-consumer education is emerging as a promising strategy to stem potential overtreatment and reduce the risk of drug harms. The value of the patient as a catalyst for driving decisions to optimize health care utilization should not be underestimated.
